Cao Fan, Cheng Ming-Han, Hu Li-Qin, Shen Hui-Hui, Tao Jin-Hui, Li Xiao-Mei, Pan Hai-Feng, Gao Jian
Department of Clinical Medicine, The Second School of Clinical Medicine, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China.
The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, China.
Pharmacol Res. 2020 Oct;160:105054. doi: 10.1016/j.phrs.2020.105054. Epub 2020 Jul 6.
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), which are characterized by self-perpetuating inflammation and tissue/organ damage, resulting from the failure of lymphocyte auto-tolerance, cause morbidity and mortality worldwide. The current drugs or therapies including conventional non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), as well as several biologic therapies such as B cell-targeted, T cell-targeted, cytokines-targeted and cytokines receptors-targeted therapy, cannot completely cure SLE and RA, and are always accompanied by unexpected side effects. Therefore, more studies have explored new methods for therapy and found that the herbal medicine as well as its natural products (NPs) exhibited promising therapeutic value through exerting effects of immunomodulation, anti-inflammation, anti-oxidation, and anti-apoptosis, etc. via regulating abnormal responses in kidney, innate and adaptive immune systems, intestine, synoviocytes, as well as bone system including chondrocytes, osteoclasts, joints and paw tissues. In the present review, we will elucidate the current mainstream drugs and therapies for SLE and RA, and summarize the efficacy and mechanisms of NPs in the treatment of SLE and RA based on available findings including in vitro and in vivo animal models, as well as clinical studies, and further analyze the existing challenges, in order to provide comprehensive evidence for improvement of SLE and RA therapy by NPs and to promote management of these two autoimmune diseases.
系统性红斑狼疮(SLE)和类风湿性关节炎(RA)以自身持续炎症和组织/器官损伤为特征,是淋巴细胞自身耐受性失效的结果,在全球范围内导致发病和死亡。目前的药物或疗法,包括传统的非甾体抗炎药(NSAIDs)和改善病情的抗风湿药(DMARDs),以及几种生物疗法,如B细胞靶向、T细胞靶向、细胞因子靶向和细胞因子受体靶向疗法,都不能完全治愈SLE和RA,而且总是伴随着意想不到的副作用。因此,更多的研究探索了新的治疗方法,并发现草药及其天然产物(NPs)通过调节肾脏、先天性和适应性免疫系统、肠道、滑膜细胞以及包括软骨细胞、破骨细胞、关节和爪组织在内的骨骼系统中的异常反应,发挥免疫调节、抗炎、抗氧化和抗凋亡等作用,展现出了有前景的治疗价值。在本综述中,我们将阐明目前治疗SLE和RA的主流药物和疗法,并根据包括体外和体内动物模型以及临床研究在内的现有研究结果,总结NPs治疗SLE和RA的疗效和机制,并进一步分析现有挑战,以便为NPs改善SLE和RA治疗提供全面证据,并促进这两种自身免疫性疾病的管理。